Company: TAK
Filing Date: 2025-06-26
Form Type: 424B5
Source: 0001395064-25-000101
Chunk: 46

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-26
Form: 424B5
Chunk 46
---
 annual report on Form 20-F and in any updates to those risk factors in its current reports on Form 6-K that are incorporated herein and in the applicable prospectus supplement, together with all of the other information appearing or incorporated by reference in this prospectus and any applicable prospectus supplement or free writing prospectus prepared by or on behalf of us or to which we refer you, in light of your particular investment objectives and financial circumstances.

### USE OF PROCEEDS
We intend to use the net proceeds from the sale of the senior debt securities described in this prospectus for general corporate purposes, unless otherwise described in the applicable prospectus supplement or free writing prospectus.

<div align='center'>-5-</div>

### CAPITALIZATION AND INDEBTEDNESS
The following table shows Takeda’s consolidated capitalization and indebtedness as of March 31, 2025.

This table should be read together with Takeda’s consolidated financial statements, including the notes thereto, and the other financial data appearing elsewhere, or incorporated by reference, in this prospectus.

|                                              |     | As of March 31, 2025 |          |
|:---------------------------------------------|:----|:---------------------|---------:|
|                                              |     | -billions of yen     |          |
| Short-term Debt:                             |     |                      |          |
| Current portion of bonds and loans           |     | ¥                    |    548.9 |
| Long-term Debt:                              |     |                      |          |
| Non-current portion of bonds and loans       |     |                      |  3,966.3 |
| Equity:                                      |     |                      |          |
| Share capital                                |     |                      |          |
| Authorized—3,500,000,000 shares;             |     |                      |          |
| Issued—1,590,949,609 shares                  |     |                      |  1,694.7 |
| Share premium                                |     |                      |  1,775.7 |
| Treasury shares                              |     |                      |    -74.8 |
| Retained earnings                            |     |                      |  1,187.6 |
| Other components of equity                   |     |                      |  2,351.9 |
| Equity attributable to owners of the Company |     |                      |  6,935.1 |
| Non-controlling interests                    |     |                      |      0.9 |
| Total equity                                 |